ISDA

Deposition Date 2009-05-13

Release Date 2009-07-28

Last Version Date 2024-05-08

Entry Detail

PDB ID:

2WIH

Keywords:

TRANSFERASE

Title:

STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125

Biological Source:

Source Organism:

HOMO SAPIENS (Taxon ID: 9606)

Host Organism:

TRICHOPLUSIA NI

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.50 Å

R-Value Free:

0.25

R-Value Work:

0.21

R-Value Observed:

0.21

Space Group:

P 62 2 2

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:CELL DIVISION PROTEIN KINASE 2
Gene (Uniprot):CDK2
Chain IDs:A, C
Chain Length:309
Number of Molecules:2
Biological Source:HOMO SAPIENS

UniProt ID:P24941 Pfam ID:PF00069 EC:2.7.11.22

Protein Blast

Polymer Type:polypeptide(L)
Molecule:CYCLIN-A2
Gene (Uniprot):CCNA2
Chain IDs:B, D
Chain Length:265
Number of Molecules:2
Biological Source:HOMO SAPIENS

UniProt ID:P20248 Pfam ID:PF00134, PF02984

Ligand Molecules

P48

SO4

Primary Citation

Identification of N,1,4,4-Tetramethyl-8-{[4-(4-Methylpiperazin-1-Yl)Phenyl]Amino}-4,5-Dihydro-1H-Pyrazolo[4,3-H]Quinazoline-3-Carboxamide (Pha-848125), a Potent, Orally Available Cyclin Dependent Kinase Inhibitor.

Brasca, M.G, Amboldi, N, Ballinari, D, Cameron, A.D, Casale, E, Cervi, G, Colombo, M, Colotta, F, Croci, V, Dalessio, R, Fiorentini, F, Isacchi, A, Mercurio, C, Moretti, W, Panzeri, A, Pastori, W, Pevarello, P, Quartieri, F, Roletto, F, Traquandi, G, Vianello, P, Vulpetti, A, Ciomei, M.Show

J.Med.Chem. 52 5152 ? (2009)

PMID: 19603809 DOI: 10.1021/JM9006559

Abstact

The discovery of a novel class of inhibitors of cyclin dependent kinases (CDKs) is described. Starting from compound 1, showing good potency as inhibitor of CDKs but being poorly selective against a panel of serine-threonine and tyrosine kinases, new analogues were synthesized. Enhancement in selectivity, antiproliferative activity against A2780 human ovarian carcinoma cells, and optimization of the physical properties and pharmacokinetic profile led to the identification of highly potent and orally available compounds. Compound 28 (PHA-848125), which in the preclinical xenograft A2780 human ovarian carcinoma model showed good efficacy and was well tolerated upon repeated daily treatments, was identified as a drug candidate for further development. Compound 28 is currently undergoing phase I and phase II clinical trials.

Legend

Protein

Chemical

Disease

Primary Citation of related structures